Header
For Healthcare Professionals
Why Jardiance Met®

Advantages of Jardiance Met®

Multiple Metabolic Benefits
Multiple Metabolic Benefits

Jardiance Met® driven by Empagliflozin offers powerful HbA1c reduction, and also offers reduction in Systolic BP and Body Weight‖2,7

Accomplish More
Accomplish More

Accomplish More with Jardiance Met®, drive by Empagliflozin, by providing strong cardio-renal protection for newly diagnosed T2DM patients1,6

Individualize Treatment
Individualize Treatment

Individualize treatment for your newly-diagnosed T2DM patients with different dosing options of Jardiance Met®1

Demonstrated Safety Profile
Demonstrated Safety Profile

Jardiance Met®, driven by Empagliflozin, combines the safety profile of Empagliflozin and metformin1

  1. Jardiance Met® India prescribing information dated April 2025.

  2. Häring HU, Merker L, Seewaldt-Becker E, et al; EMPA-REG MET Trial Investigators. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37(6):1650-1659.

  3. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. (EMPA-REG OUTCOME® results and the publication’s Supplementary Appendix for certain baseline characteristics.)

  4. Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with Empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424. (EMPEROR-Reduced results and the publication’s Supplementary Appendix.)

  5. Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. (EMPEROR-Preserved results and the publication’s Supplementary Appendix.)

  6. Wanner C, Inzucchi SE, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323-334.

  7. Hadjadj S, Rosenstock J, Meinicke T, et al; Initial Combination of Empagliflozin and Metformin in Patients with Type 2 Diabetes. Diabetes Care. 2016;39(10):1718-1728.

  • *
    In a 24-week, double-blind, placebo-controlled study of 637 patients with T2D, the efficacy and safety of JARDIANCE 10 mg (n=217) and JARDIANCE 25 mg (n=213) as add-on therapy to metformin ≥ 1500 mg were evaluated vs placebo added to metformin (n=207). The primary endpoint was adjusted mean change (SE) from baseline in HbA1c (%); weight loss and blood pressure reduction were key secondary and exploratory endpoints, respectively. Adjusted mean changes of –0.1% from baseline HbA1c 7.9% for placebo (n=207), –0.7% from baseline HbA1c 7.9% for JARDIANCE 10 mg (n=217), and –0.8% from baseline HbA1c 7.9% for JARDIANCE 25 mg (n=213), respectively. Difference from placebo (adjusted mean) was –0.6% for both JARDIANCE 10 mg and 25 mg; p<0.001 vs placebo for both doses. Adjusted mean change in systolic blood pressure from baseline at 24 weeks: JARDIANCE 10 mg –4.5 mmHg (n=217), JARDIANCE 25 mg –5.2 mmHg (n=213), vs placebo –0.4 mmHg (n=207). Adjusted mean changes of –0.45 kg reduction in body weight from baseline 79.7 kg for placebo (n=207), –2.08 kg from baseline 81.6 kg for JARDIANCE 10 mg (n=217), and –2.46 kg from baseline 82.2 kg for JARDIANCE 25 mg (n=213), respectively; p<0.0001 vs placebo for both doses.1,2
  • †
    The primary composite outcome in the EMPA-REG OUTCOME® trial was 3-point MACE, composed of death from CV causes, nonfatal MI, or nonfatal stroke, as analysed in the pooled JARDIANCE group vs the placebo group. Patients were adults with insufficiently controlled T2D and CAD, PAD, or a history of MI or stroke. The 14% RRR in 3-point MACE (HR=0.86; 95% CI: 0.74, 0.99; p<0.001 for noninferiority; p=0.04 for superiority) was driven by a reduction in the risk of CV death (HR=0.62; 95% CI: 0.49, 0.77); there was no change in risk of nonfatal MI (HR=0.87; 95% CI: 0.70, 1.09) or nonfatal stroke (HR=1.24; 95% CI: 0.92, 1.67).1,3
  • ‡
    In the EMPEROR-Reduced trial, a randomised, double-blind, parallel-group, placebo-controlled study of 3730 patients with HFrEF, the efficacy and safety of JARDIANCE 10 mg (n=1863) were evaluated vs placebo (n=1867). Patients were adults with chronic heart failure (NYHA class II, III, or IV) and reduced ejection fraction (LVEF ≤ 40%). The primary endpoint in the EMPEROR-Reduced trial was a composite of CV death or HHF, analysed as time to the first event. Patients treated with JARDIANCE experienced a 25% RRR in this endpoint (HR=0.75; 95% CI: 0.65, 0.86; p<0.001). In the EMPEROR Preserved trial, a randomised, double-blind, parallel-group, placebo-controlled study of 5988 patients with HFpEF, the efficacy and safety of JARDIANCE 10 mg (n=2997) were evaluated vs placebo (n=2991). Patients were adults with chronic heart failure (NYHA class II, III, or IV) and preserved ejection fraction (LVEF > 40%). The primary endpoint in the EMPEROR-Preserved trial was a composite of CV death or HHF, analysed as time to the first event. Patients treated with JARDIANCE experienced a 21% RRR in this endpoint (HR=0.79; 95% CI: 0.69, 0.90; p<0.001).4,5
  • §
    Incident or worsening nephropathy is defined as progression to macroalbuminuria, doubling of serum creatinine, eGFR of ≤ 45 mL/min/1.73 m2; initiation of renal replacement therapy; death from renal disease. Incident or worsening nephropathy was a prespecified component of the secondary microvascular outcome in the EMPA-REG OUTCOME® trial.6
  • ‖
    JARDIANCE and Jardiance Met® are not indicated for weight loss or reduction of blood pressure.2,7